<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc='http://purl.org/dc/elements/1.1/' xmlns:oai_dc='http://www.openarchives.org/OAI/2.0/oai_dc/' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xsi:schemaLocation='http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd'>
<dc:creator>Caraman, N.C.</dc:creator>
<dc:date>2023</dc:date>
<dc:description xml:lang='en'><p>Hypertension and diabetes are components of metabolic syndrome. The coexistence of these two diseases is associated with increased risk of cardio-vascular events. The microvascular and macrovascular complications are signi-ficantly more common unfavourable cardiovascular events. The first line of anti-hypertensive drug classes includ angiotensin-converting enzyme inhibitors, an-giotensin receptor blockers, calcium channel blockers, thiazide-like diuretics, mi-neralocorticoid receptor antagonists, and beta-blockers. The second-line anti-hypertensive drugs include &alpha;-blockers, renin inhibitors, loop diuretics, substan-ces affecting the central nervous system (methyldopa, clonidine), and vasodila-tors. The exact choice of hypotensive drugs depends on various factors: comorbi-dities, estimated glomerular filtration rate, side effects and ethnicity.</p></dc:description>
<dc:source>Interuniversitaria (Ediția 19, Vol.3) 139-149</dc:source>
<dc:subject>hypertension</dc:subject>
<dc:subject>diabetes mellitus</dc:subject>
<dc:subject>antihypertensive drugs</dc:subject>
<dc:subject>antihy-pertensive effect</dc:subject>
<dc:subject>metabolic disturbances</dc:subject>
<dc:title>Preparatele antihipertensive la pacienții cu diabet zaharat</dc:title>
<dc:type>info:eu-repo/semantics/article</dc:type>
</oai_dc:dc>